Michalska Dziama, PatrycjaBuendia, IzaskunAlmale Del Barrio, LauraLeón Martínez, Rafael2024-01-312024-01-312016-06-191568-026610.2174/1568026616666160927154116https://hdl.handle.net/20.500.14352/97112Alzheimer's disease (AD) is the most prevalent among the aging diseases known as neurodegenerative disorders. Drug design programs over the last two decades were mainly based on the cholinergic, the amyloid or the tau hypothesis. However, none of the new drugs have a real impact on the outcome of the disease. The complex nature of AD has led to new approaches for drug development programs, the multitarget drug design hypothesis. Based on this hypothesis, the generation of multitarget hybrid compounds from previously known active molecules has been one of the most widely used to obtain new candidates for the future treatment of AD. Here, we summarize recent developments based on the hybridization hypothesis to obtain a potential clinical candidate for AD.engjournal article1873-4294https://doi.org/10.2174/1568026616666160927154116restricted access615:54615.31Alzheimer's diseaseHybrid compoundsDrug designMultitarget drugsEmerging targets for ADDual AChE InhibitorsAntioxidantsNrf2-EpRE inducersCiencias Biomédicas24 Ciencias de la Vida